anticalin


Also found in: Wikipedia.

anticalin

A protein derived from a lipocalin (also known as cytosolic fatty acid binding protein) which is genetically engineered to modify its binding properties. Anticalins have the advantage of a monoclonal antibody’s specificity for small lipid molecules (e.g., steroids, bilins, retinoids and lipids), better tissue penetration and thermostability, but without the large size (they are 8-fold smaller) and can also batched in E coli, eliminating the need for animal extraction..
References in periodicals archive ?
PRS-060, an Anticalin targeting IL4Ra for the treatment of asthma, has achieved in vivo proof of concept.
Anti-VEGF PRS-050 is First Anticalin Tested in Humans
Pieris AG announced today preclinical in vitro and in vivo data for its PRS-080 Anticalin antagonist program targeting hepcidin, a small peptide which plays a pivotal role in the regulation of iron levels in the blood.
As the company builds and expands its internal and partnered Anticalin pipeline, Laurent's contribution will be significant.
FREISING, Germany, April 12, 2011 /PRNewswire/ -- Pieris AG announced today the signature of a collaboration and license agreement with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), under which Pieris will apply its proprietary Anticalin scaffold technology to discover novel Anticalins against two Daiichi Sankyo targets.
We are delighted to have Steve on board to help drive the value of Pieris' proprietary Anticalin technology", commented Dr.
Pieris exclusively owns the Anticalin patent estate, which offers complete freedom to operate outside the patent boundaries defined by conventional antibody products.
Pieris' Anticalin technology complements our existing capabilities by enabling a novel approach to targets where differentiation from traditional antibodies is required," stated Dr.
com/) announced today the signature of a collaboration and license agreement with both Sanofi-Aventis and Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), under which Pieris will apply its proprietary Anticalin technology to discover novel Anticalin drugs against multiple targets, with further development undertaken by Sanofi-Aventis and Sanofi-Pasteur.
PRS-050, an Anticalin with extended serum half-life, exhibits comparable binding and functional in vitro activity to currently approved VEGF antagonists.
The results provide an indication that an Anticalin approach to antagonizing the c-Met pathway may be of significant therapeutic value in treating cancer.
Under its manufacturing agreement with Wacker Biotech GmbH, a full-service contract manufacturer of biopharmaceuticals, Pieris has successfully completed the first cGMP run of its Anticalin candidate PRS-050, a potent VEGF antagonist with broad therapeutic applicability.